inclusion criteria: 1. availability of the informed consent form of the patient information leaflet (pil) signed and dated by patient. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. confirmed case of covid-19 at the time of screening based on sars-cov-2 rna test using nucleic acid amplification (naa) method. it is acceptable to include a patient with a presumptive covid-19 diagnosis prior to receiving the results of sars-cov-2 rna test made at the screening stage. 4. hospital admission due to covid-19. 5. moderate severity infection with sars-cov-2: * clinical signs: * mandatory: ct pattern typical of a viral lesion (lesion volume is minimal or moderate; ct 1-2). * additional (at least 1 of the following criteria): * body temperature \> 38 °c; * rr \> 22/min; * shortness of breath on exertion; * spo2 \< 95%; * serum crp \> 10 mg/l. 6. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide. for men (optional): consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion. women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.

inclusion criteria: 1. availability of the informed consent form of the patient information leaflet (pil) signed and dated by patient. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. confirmed case of covid-19 at the time of screening based on sars-cov-2 rna test using nucleic acid amplification (naa) method. it is acceptable to include a patient with a presumptive covid-19 diagnosis prior to receiving the results of sars-cov-2 rna test made at the screening stage. 4. hospital admission due to covid-19. 5. moderate severity infection with sars-cov-2: * clinical signs: * mandatory: ct pattern typical of a viral lesion (lesion volume is minimal or moderate; ct 1-2). * additional (at least 1 of the following criteria): * body temperature \> 38 °c; * rr \> 22/min; * shortness of breath on exertion; * spo2 \< 95%; * serum crp \> 10 mg/l. 6. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide. for men (optional): consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion. women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.

inclusion criteria: availability of the informed consent form of the patient information leaflet (pil) signed and dated by patient. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. confirmed case of covid-19 at the time of screening based on sars-cov-2 rna test using nucleic acid amplification (naa) method. it is acceptable to include a patient with a presumptive covid-19 diagnosis prior to receiving the results of sars-cov-2 rna test made at the screening stage. hospital admission due to covid-19. moderate severity infection with sars-cov-2: clinical signs: mandatory: ct pattern typical of a viral lesion (lesion volume is minimal or moderate; ct 1-2). additional (at least 1 of the following criteria): body temperature > 38 °c; rr > 22/min; shortness of breath on exertion; spo2 < 95%; serum crp > 10 mg/l. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide. for men (optional): consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion. women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.

inclusion criteria: availability of the informed consent form of the patient information leaflet (pil) signed and dated by patient. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. confirmed case of covid-19 at the time of screening based on sars-cov-2 rna test using nucleic acid amplification (naa) method. it is acceptable to include a patient with a presumptive covid-19 diagnosis prior to receiving the results of sars-cov-2 rna test made at the screening stage. hospital admission due to covid-19. moderate severity infection with sars-cov-2: clinical signs: mandatory: ct pattern typical of a viral lesion (lesion volume is minimal or moderate; ct 1-2). additional (at least 1 of the following criteria): body temperature > 38 °c; rr > 22/min; shortness of breath on exertion; spo2 < 95%; serum crp > 10 mg/l. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide. for men (optional): consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion. women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.